ACADIA Pharmaceuticals Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines targeting unmet medical needs in central nervous system disorders and rare diseases; its commercial portfolio features NUPLAZID (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), the first and only FDA-approved treatment for Rett syndrome in patients aged two years and older. The company advances a robust pipeline including mid- to late-stage candidates such as ACP-204 for Lewy body dementia psychosis and programs in Alzheimer's disease psychosis, alongside earlier-stage efforts addressing Prader-Willi syndrome negative symptoms, treatment-resistant depression (ACP-211), Huntington's disease and tardive dyskinesia (ACP-271), and essential tremor (ACP-711). ACADIA operates primarily in the United States and Canada, with international expansion underway including a Phase 3 trial of trofinetide for Rett syndrome in Japan; founded in 1993 as Receptor Technologies in Vermont and relocated to San Diego, California, in 1997, the company maintains headquarters at 12830 El Camino Real, Suite 400, San Diego, CA 92130. Recent developments include the initiation of a Phase 2 study for ACP-204 in Lewy body dementia psychosis and the Phase 3 Japan trial for trofinetide in 2025; appointment of Catherine Owen Adams as Chairperson of the Biotechnology Innovation Organization's Emerging Companies section and Executive Committee member; addition of Konstantina Katcheves as Senior Vice President and Chief Business and Strategy Officer to drive global partnerships and pipeline growth; extension of NUPLAZID patent protection to 2038; and an agreement in late 2024 to sell its rare pediatric disease priority review voucher for $150 million to fund commercial operations, R&D, and business development.
Company News
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Avidity Partners Management LP Sells 93,933 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?